FTC Sues Prescription Drug Middlemen for Artificially Inflating …
Sep 20, 2024 — Today, the Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group pur.
Federal Trade Commission sues largest drug middlemen for …
Sep 20, 2024 — The agency alleges that CVS Health’s Caremark Rx, Cigna’s Express Scripts and UnitedHealth Group’s Optum Rx and their affiliated group purchasing organizations created a system that prioritizes...
Federal Trade Commission accuses three drug middlemen of …
Sep 21, 2024 — The FTC accused the "Big Three" pharmacy benefit managers (PBMs) — UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts — of "engaging in anticompetitive and...
Express Scripts® Further Advances Transparency and …
Apr 13, 2023 — Express Scripts’ new Copay Assurance™ plan ensures consumers pay less out-of-pocket by capping copays on prescription drugs at $5 for generics, $25 for preferred brand drugs, and $45 for ...
Express Scripts Sues Federal Trade Commission And Chair Over
Oct 3, 2024 — On September 17, 2024, Express Scripts Inc.—the nation's third-largest pharmacy benefits manager (PBM) by patient population—filed suit against the Federal Trade Commission (FTC) and Chairperson Lina Kahn, challenging the accuracy and legal sufficiency of the FTC's July 9, 2024, interim report.
PBM practices spark outrage and protests outside Express Scripts
May 17, 2024 — Hoey said Express Scripts reimburses independent pharmacists at a loss on eight out of every 10 prescriptions they dispense. As a result, he said, more than 500 independent pharmacies have...
Express Scripts Sues FTC Over Report on Pharmacy Benefit Management ...
Oct 3, 2024 — On September 17, Express Scripts, Inc. (“Express Scripts”), one of the largest pharmacy benefit managers (PBMs) in the United States, brought suit against the Federal Trade Commission (“FTC”) over its July 2024 interim report on the PBM industry.
Express Scripts Sues FTC, Demands Withdrawal of PBM Report
Sep 17, 2024 — For more than two years, Express Scripts fully cooperated with the FTC study into the PBM industry, meeting the agency's extensive demands for data and information. The FTC's report...
Express Scripts Adds Three Biosimilars to Largest Formulary to …
Jul 10, 2023 — Express Scripts will prefer the following biosimilar products on its NPF, offering competitive alternatives to HUMIRA (adalimumab): Cyltezo (adalimumab-adbm) (Boehringer Ingelheim), the first...
In Wake of Express Scripts Suit, FTC Takes On 3 Largest PBMs
Oct 13, 2024 — Days after Express Scripts sued the Federal Trade Commission (FTC) over the publication of a report criticizing pharmacy benefit managers (PBMs), the FTC took legal action of its own,...